0
Clinical Investigations: TUBERCULOSIS |

Comparative Roles of Levofloxacin and Ofloxacin in the Treatment of Multidrug-Resistant Tuberculosis*: Preliminary Results of a Retrospective Study From Hong Kong

Wing Wai Yew; Chi Kuen Chan; Chi Chiu Leung; Chi Hung Chau; Cheuk Ming Tam; Poon Chuen Wong; Joseph Lee
Author and Funding Information

*From the Tuberculosis & Chest Unit (Drs. Yew, Chau, Wong, and Lee), Grantham Hospital; and Tuberculosis Service (Drs. Chan, Leung, and Tam), Department of Health, Wanchai Chest Clinic, Hong Kong, China.

Correspondence to: Wing Wai Yew, MB, FCCP, Tuberculosis & Chest Unit, Grantham Hospital, 125 Wong Chuk Hang Rd, Aberdeen, Hong Kong, China; e-mail: wwyew@ha.org.hk



Chest. 2003;124(4):1476-1481. doi:10.1378/chest.124.4.1476
Text Size: A A A
Published online

Objective: To compare levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis (MDR-TB).

Patients and methods: A retrospective analysis of 106 patients with MDR-TB (February 1990 through December 2000) receiving directly observed therapy with fluoroquinolone and accompanying drugs, which mainly included aminoglycosides, cycloserine, ethionamide/prothionamide, and pyrazinamide, was performed. Clinical data from 99 suitable patients were subjected to univariate analysis, stratification, and multiple logistic regression to compare the roles of levofloxacin and ofloxacin in multidrug regimens.

Results: Forty patients received 612.5 ± 79.0 mg qd levofloxacin (mean ± SD), and 59 patients received 628.8 ± 101.8 mg qd ofloxacin together with similar active second-line drugs for similar durations. The times to sputum smear (both 1.8 months) and culture conversion (both 2.1 months) were equivalent. Adverse reactions occurred at similar rates (10.0% vs 11.9%). The combined treatment success rate was 83.8%, being higher among ofloxacin-susceptible than ofloxacin-resistant cases (90.5% vs 64.0%, p < 0.01). The success rates for the levofloxacin group were 90.0% (overall), 96.2% (ofloxacin-susceptible cases), and 78.6% (ofloxacin-resistant cases) in comparison with 79.7%, 87.5%, and 45.5%, respectively, for the ofloxacin group (Mantel-Haenszel common odds ratio estimate, 4.0; p < 0.05). Bacillary susceptibility to ofloxacin, good adherence, radiographic extent of one lung or less, and use of levofloxacin were independent predictors of favorable outcome (odds ratios, 7.6 to 21.3). One patient each from both groups relapsed.

Conclusion: Levofloxacin was found to be more efficacious than ofloxacin when incorporated into multidrug regimens used for treatment of MDR-TB.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
Treatment of urinary tract infections in nonpregnant women.
American College of Obstetricians and Gynecologists | 9/19/2008
Acute rhinosinusitis in adults.
University of Michigan Health System | 9/5/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543